News

Press Releases
Back to Press Releases >
BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
06/12/2012
BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah

Jupiter, Fla. – June 21, 2012 – BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTCQB: BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today that it has entered into a Research Agreement with the University of Utah (”University”). Pursuant to the agreement, the University is to provide research services relating to the identification of brown fat tissue and the development and characterization of brown fat cell lines.

Pursuant to the terms of the Research Agreement, all inventions, discoveries, patent rights, information, data, methods and techniques, including all cell lines, cell culture media and derivatives thereof, shall be owned by BRT.

The research and development that will be performed at the University, under the supervision of Dr. Amit Patel, will be used for the eventual filing of an IND with the FDA for a Phase 1 clinical trial.

The agreement was entered into in connection with the Company’s ThermoStem™ Program, which focuses on treatments for metabolic disorders, such as diabetes and heart disease, and obesity. The ThermoStem™ Program employs the use of brown fat, which initial research indicates has a role in maintaining metabolism and provides the potential for a cell based therapeutic for the treatment of diabetes.

Mark Weinreb, Chief Executive Officer of the Company, stated, “This agreement marks a significant milestone for our ThermoStem™ Program. All ongoing pre‐clinical work, brown fat data and future research for the foreseeable future is now defined and contemplated through this agreement. It provides a roadmap for potential publications, grants, and ultimately, clinical trials, so that we may start testing for a brown fat stem cell‐based approach to treat certain metabolic disorders and obesity.”

BioRestorative Therapies: A Stem Cell Biotechnology Company